Stem definition | Drug id | CAS RN |
---|---|---|
2705 | 124937-51-5 |
Dose | Unit | Route |
---|---|---|
4 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 12 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.58 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 8.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 25, 1998 | FDA | PHARMACIA AND UPJOHN |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 112.04 | 11.79 | 280 | 22737 | 240233 | 56028817 |
Sensitivity to weather change | 98.36 | 11.79 | 50 | 22967 | 6599 | 56262451 |
Urinary incontinence | 96.87 | 11.79 | 87 | 22930 | 29498 | 56239552 |
Multiple sclerosis | 83.69 | 11.79 | 78 | 22939 | 27724 | 56241326 |
Multiple sclerosis relapse | 82.95 | 11.79 | 97 | 22920 | 44806 | 56224244 |
Dry mouth | 79.82 | 11.79 | 114 | 22903 | 64091 | 56204959 |
Fall | 72.87 | 11.79 | 314 | 22703 | 357196 | 55911854 |
Pollakiuria | 72.58 | 11.79 | 69 | 22948 | 25133 | 56243917 |
Hypertonic bladder | 65.01 | 11.79 | 30 | 22987 | 3202 | 56265848 |
Maternal exposure during pregnancy | 58.92 | 11.79 | 5 | 23012 | 189548 | 56079502 |
Contraindicated product administered | 55.03 | 11.79 | 6 | 23011 | 186280 | 56082770 |
Bladder disorder | 53.54 | 11.79 | 36 | 22981 | 7988 | 56261062 |
Nocturia | 47.70 | 11.79 | 32 | 22985 | 7074 | 56261976 |
Antinuclear antibody negative | 47.03 | 11.79 | 12 | 23005 | 204 | 56268846 |
Treatment failure | 46.67 | 11.79 | 7 | 23010 | 170385 | 56098665 |
Coombs positive haemolytic anaemia | 45.99 | 11.79 | 13 | 23004 | 331 | 56268719 |
Off label use | 40.82 | 11.79 | 106 | 22911 | 556074 | 55712976 |
Glossodynia | 37.98 | 11.79 | 8 | 23009 | 152450 | 56116600 |
Drug intolerance | 37.40 | 11.79 | 32 | 22985 | 264786 | 56004264 |
Herpes simplex reactivation | 37.08 | 11.79 | 12 | 23005 | 488 | 56268562 |
Cerebrovascular accident | 35.48 | 11.79 | 105 | 22912 | 99165 | 56169885 |
Infusion related reaction | 35.05 | 11.79 | 21 | 22996 | 208910 | 56060140 |
Systemic lupus erythematosus | 34.84 | 11.79 | 15 | 23002 | 180063 | 56088987 |
Exposure during pregnancy | 34.28 | 11.79 | 7 | 23010 | 136335 | 56132715 |
Hallucination, auditory | 34.03 | 11.79 | 32 | 22985 | 11492 | 56257558 |
Paranoia | 33.98 | 11.79 | 31 | 22986 | 10713 | 56258337 |
Stress urinary incontinence | 31.25 | 11.79 | 16 | 23001 | 2142 | 56266908 |
Wound | 31.23 | 11.79 | 9 | 23008 | 138795 | 56130255 |
Micturition urgency | 31.08 | 11.79 | 27 | 22990 | 8754 | 56260296 |
Rheumatoid arthritis | 30.31 | 11.79 | 70 | 22947 | 382534 | 55886516 |
Bladder spasm | 29.89 | 11.79 | 14 | 23003 | 1545 | 56267505 |
Depression | 29.77 | 11.79 | 149 | 22868 | 179968 | 56089082 |
Urinary retention | 29.36 | 11.79 | 46 | 22971 | 28028 | 56241022 |
Balance disorder | 29.32 | 11.79 | 83 | 22934 | 76437 | 56192613 |
Gastritis haemorrhagic | 28.01 | 11.79 | 13 | 23004 | 1406 | 56267644 |
Dizziness | 27.96 | 11.79 | 255 | 22762 | 375885 | 55893165 |
Transient ischaemic attack | 27.10 | 11.79 | 49 | 22968 | 33528 | 56235522 |
Hyperlipidaemia | 26.79 | 11.79 | 35 | 22982 | 18074 | 56250976 |
Antiphospholipid syndrome | 26.36 | 11.79 | 13 | 23004 | 1608 | 56267442 |
Coronary artery disease | 26.21 | 11.79 | 46 | 22971 | 30750 | 56238300 |
Abdominal discomfort | 25.98 | 11.79 | 46 | 22971 | 277228 | 55991822 |
Gastrooesophageal reflux disease | 25.97 | 11.79 | 84 | 22933 | 83173 | 56185877 |
Complex regional pain syndrome | 23.06 | 11.79 | 13 | 23004 | 2110 | 56266940 |
Oesophagitis | 22.09 | 11.79 | 28 | 22989 | 14029 | 56255021 |
Swelling | 21.37 | 11.79 | 41 | 22976 | 239730 | 56029320 |
Pericarditis | 21.17 | 11.79 | 9 | 23008 | 108914 | 56160136 |
Incontinence | 21.17 | 11.79 | 24 | 22993 | 10711 | 56258339 |
Hepatic enzyme increased | 20.41 | 11.79 | 24 | 22993 | 171360 | 56097690 |
Gait disturbance | 20.22 | 11.79 | 125 | 22892 | 163196 | 56105854 |
Mental status changes | 19.89 | 11.79 | 46 | 22971 | 37455 | 56231595 |
Hypothyroidism | 19.33 | 11.79 | 46 | 22971 | 38150 | 56230900 |
Infection | 18.93 | 11.79 | 33 | 22984 | 200173 | 56068877 |
Anxiety disorder | 18.27 | 11.79 | 14 | 23003 | 3806 | 56265244 |
Pain | 18.01 | 11.79 | 179 | 22838 | 663005 | 55606045 |
Myocardial infarction | 17.62 | 11.79 | 80 | 22937 | 92790 | 56176260 |
Urge incontinence | 17.45 | 11.79 | 8 | 23009 | 841 | 56268209 |
Product use issue | 17.29 | 11.79 | 31 | 22986 | 186010 | 56083040 |
White blood cell count abnormal | 16.76 | 11.79 | 16 | 23001 | 5851 | 56263199 |
Iliac artery occlusion | 16.66 | 11.79 | 5 | 23012 | 158 | 56268892 |
Constipation | 16.56 | 11.79 | 140 | 22877 | 201803 | 56067247 |
Stomatitis | 16.55 | 11.79 | 15 | 23002 | 120795 | 56148255 |
Barrett's oesophagus | 16.54 | 11.79 | 7 | 23010 | 608 | 56268442 |
Secondary progressive multiple sclerosis | 16.52 | 11.79 | 9 | 23008 | 1366 | 56267684 |
Osteonecrosis | 16.39 | 11.79 | 32 | 22985 | 23183 | 56245867 |
Liver iron concentration abnormal | 16.27 | 11.79 | 4 | 23013 | 58 | 56268992 |
Toxicity to various agents | 16.25 | 11.79 | 43 | 22974 | 224521 | 56044529 |
Peritonitis | 16.18 | 11.79 | 26 | 22991 | 16176 | 56252874 |
Drug abuse | 15.92 | 11.79 | 4 | 23013 | 67606 | 56201444 |
Dysphagia | 15.85 | 11.79 | 71 | 22946 | 81876 | 56187174 |
Aphonia | 15.83 | 11.79 | 19 | 22998 | 9010 | 56260040 |
Completed suicide | 15.65 | 11.79 | 19 | 22998 | 133814 | 56135236 |
Neutrophil count abnormal | 15.51 | 11.79 | 11 | 23006 | 2659 | 56266391 |
Cardiac failure congestive | 15.49 | 11.79 | 74 | 22943 | 87646 | 56181404 |
Body temperature fluctuation | 15.45 | 11.79 | 10 | 23007 | 2082 | 56266968 |
Drug hypersensitivity | 15.34 | 11.79 | 176 | 22841 | 275029 | 55994021 |
Mixed incontinence | 14.97 | 11.79 | 4 | 23013 | 82 | 56268968 |
Confusional state | 14.85 | 11.79 | 140 | 22877 | 208015 | 56061035 |
Product complaint | 14.77 | 11.79 | 21 | 22996 | 11739 | 56257311 |
Malignant neoplasm progression | 14.43 | 11.79 | 6 | 23011 | 73581 | 56195469 |
Varicose ulceration | 14.34 | 11.79 | 6 | 23011 | 506 | 56268544 |
Neurogenic bladder | 14.26 | 11.79 | 11 | 23006 | 3018 | 56266032 |
Colitis ischaemic | 14.25 | 11.79 | 19 | 22998 | 10001 | 56259049 |
Haemoglobin abnormal | 14.01 | 11.79 | 13 | 23004 | 4591 | 56264459 |
Discomfort | 13.73 | 11.79 | 23 | 22994 | 141738 | 56127312 |
Arthropathy | 13.27 | 11.79 | 40 | 22977 | 200235 | 56068815 |
Neutropenia | 13.26 | 11.79 | 28 | 22989 | 158139 | 56110911 |
Blister | 13.22 | 11.79 | 15 | 23002 | 108872 | 56160178 |
Increased appetite | 13.10 | 11.79 | 17 | 23000 | 8718 | 56260332 |
Perforation | 13.00 | 11.79 | 7 | 23010 | 1039 | 56268011 |
Escherichia urinary tract infection | 12.91 | 11.79 | 19 | 22998 | 10956 | 56258094 |
Chronic obstructive pulmonary disease | 12.85 | 11.79 | 52 | 22965 | 57363 | 56211687 |
Irritable bowel syndrome | 12.76 | 11.79 | 6 | 23011 | 68452 | 56200598 |
Visual impairment | 12.67 | 11.79 | 62 | 22955 | 74140 | 56194910 |
Psychotic disorder | 12.60 | 11.79 | 29 | 22988 | 23529 | 56245521 |
Skin disorder | 12.58 | 11.79 | 31 | 22986 | 26278 | 56242772 |
Pathological fracture | 12.53 | 11.79 | 16 | 23001 | 8073 | 56260977 |
Therapy non-responder | 12.50 | 11.79 | 54 | 22963 | 61301 | 56207749 |
Febrile neutropenia | 12.32 | 11.79 | 15 | 23002 | 105530 | 56163520 |
Cystitis | 12.26 | 11.79 | 46 | 22971 | 48992 | 56220058 |
Haemoglobin | 12.12 | 11.79 | 4 | 23013 | 173 | 56268877 |
Blood triglycerides increased | 12.02 | 11.79 | 19 | 22998 | 11658 | 56257392 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seronegative arthritis | 66.08 | 15.20 | 19 | 7080 | 957 | 31689288 |
Lipoma | 57.50 | 15.20 | 19 | 7080 | 1524 | 31688721 |
Pollakiuria | 51.55 | 15.20 | 38 | 7061 | 17864 | 31672381 |
Dry mouth | 51.18 | 15.20 | 43 | 7056 | 24415 | 31665830 |
Fall | 46.90 | 15.20 | 118 | 6981 | 185971 | 31504274 |
Urinary incontinence | 45.94 | 15.20 | 35 | 7064 | 17285 | 31672960 |
Prostatic specific antigen increased | 41.84 | 15.20 | 30 | 7069 | 13508 | 31676737 |
Urinary retention | 39.43 | 15.20 | 43 | 7056 | 33682 | 31656563 |
Inflammatory marker increased | 39.17 | 15.20 | 19 | 7080 | 4159 | 31686086 |
Balance disorder | 39.11 | 15.20 | 45 | 7054 | 37377 | 31652868 |
Musculoskeletal discomfort | 32.45 | 15.20 | 20 | 7079 | 7003 | 31683242 |
Micturition urgency | 30.75 | 15.20 | 18 | 7081 | 5742 | 31684503 |
Multiple sclerosis | 29.98 | 15.20 | 20 | 7079 | 8017 | 31682228 |
Urinary tract infection | 22.78 | 15.20 | 52 | 7047 | 76817 | 31613428 |
Confusional state | 21.35 | 15.20 | 72 | 7027 | 133262 | 31556983 |
Failure to thrive | 20.90 | 15.20 | 16 | 7083 | 7946 | 31682299 |
Bladder disorder | 20.77 | 15.20 | 11 | 7088 | 2891 | 31687354 |
Asthenia | 20.56 | 15.20 | 102 | 6997 | 224653 | 31465592 |
Cerebrovascular accident | 20.56 | 15.20 | 51 | 7048 | 79433 | 31610812 |
Nocturia | 18.82 | 15.20 | 16 | 7083 | 9219 | 31681026 |
Faecaloma | 18.37 | 15.20 | 12 | 7087 | 4644 | 31685601 |
Gait inability | 18.29 | 15.20 | 22 | 7077 | 19122 | 31671123 |
Multiple sclerosis relapse | 17.00 | 15.20 | 17 | 7082 | 12030 | 31678215 |
Incontinence | 16.78 | 15.20 | 12 | 7087 | 5374 | 31684871 |
Hypertonic bladder | 16.61 | 15.20 | 8 | 7091 | 1722 | 31688523 |
Dizziness | 16.54 | 15.20 | 88 | 7011 | 199059 | 31491186 |
Blood pressure systolic increased | 16.39 | 15.20 | 21 | 7078 | 19449 | 31670796 |
Rectal tenesmus | 15.44 | 15.20 | 6 | 7093 | 768 | 31689477 |
Toxicity to various agents | 15.33 | 15.20 | 11 | 7088 | 181476 | 31508769 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis | 101.59 | 11.96 | 76 | 22905 | 25209 | 70880254 |
Urinary tract infection | 100.84 | 11.96 | 238 | 22743 | 248531 | 70656932 |
Urinary incontinence | 90.02 | 11.96 | 84 | 22897 | 37758 | 70867705 |
Sensitivity to weather change | 89.36 | 11.96 | 45 | 22936 | 7360 | 70898103 |
Fall | 81.15 | 11.96 | 321 | 22660 | 443775 | 70461688 |
Multiple sclerosis relapse | 73.83 | 11.96 | 80 | 22901 | 42937 | 70862526 |
Pollakiuria | 64.12 | 11.96 | 66 | 22915 | 33395 | 70872068 |
Bladder disorder | 57.57 | 11.96 | 35 | 22946 | 8254 | 70897209 |
Dry mouth | 53.66 | 11.96 | 88 | 22893 | 70369 | 70835094 |
Cerebrovascular accident | 50.33 | 11.96 | 130 | 22851 | 143340 | 70762123 |
Lipoma | 49.05 | 11.96 | 22 | 22959 | 2780 | 70902683 |
Hypertonic bladder | 48.63 | 11.96 | 24 | 22957 | 3759 | 70901704 |
Balance disorder | 42.86 | 11.96 | 92 | 22889 | 90036 | 70815427 |
Off label use | 40.39 | 11.96 | 116 | 22865 | 742944 | 70162519 |
Micturition urgency | 36.75 | 11.96 | 30 | 22951 | 11284 | 70894179 |
Seronegative arthritis | 36.33 | 11.96 | 19 | 22962 | 3360 | 70902103 |
Urinary retention | 35.22 | 11.96 | 62 | 22919 | 52458 | 70853005 |
Dizziness | 33.55 | 11.96 | 261 | 22720 | 463880 | 70441583 |
Drug abuse | 31.47 | 11.96 | 5 | 22976 | 147251 | 70758212 |
Prostatic specific antigen increased | 30.53 | 11.96 | 25 | 22956 | 9441 | 70896022 |
Toxicity to various agents | 30.46 | 11.96 | 48 | 22933 | 382124 | 70523339 |
Incontinence | 29.21 | 11.96 | 28 | 22953 | 13000 | 70892463 |
Hallucination, auditory | 26.18 | 11.96 | 31 | 22950 | 18297 | 70887166 |
Bladder spasm | 25.96 | 11.96 | 13 | 22968 | 2100 | 70903363 |
Contraindicated product administered | 25.74 | 11.96 | 6 | 22975 | 134606 | 70770857 |
Stress urinary incontinence | 25.67 | 11.96 | 12 | 22969 | 1668 | 70903795 |
Maternal exposure during pregnancy | 24.46 | 11.96 | 4 | 22977 | 115341 | 70790122 |
Musculoskeletal discomfort | 23.58 | 11.96 | 29 | 22952 | 17803 | 70887660 |
Nocturia | 23.24 | 11.96 | 24 | 22957 | 12180 | 70893283 |
Treatment failure | 22.91 | 11.96 | 9 | 22972 | 144133 | 70761330 |
Febrile neutropenia | 22.31 | 11.96 | 20 | 22961 | 204298 | 70701165 |
Secondary progressive multiple sclerosis | 21.62 | 11.96 | 10 | 22971 | 1357 | 70904106 |
Confusional state | 21.09 | 11.96 | 161 | 22820 | 284237 | 70621226 |
Paranoia | 21.08 | 11.96 | 27 | 22954 | 17261 | 70888202 |
Inflammatory marker increased | 20.92 | 11.96 | 20 | 22961 | 9254 | 70896209 |
Asthenia | 20.74 | 11.96 | 233 | 22748 | 457433 | 70448030 |
Systemic lupus erythematosus | 20.59 | 11.96 | 4 | 22977 | 101898 | 70803565 |
Gait inability | 18.90 | 11.96 | 45 | 22936 | 47130 | 70858333 |
Transient ischaemic attack | 18.59 | 11.96 | 44 | 22937 | 45900 | 70859563 |
Hand deformity | 18.33 | 11.96 | 3 | 22978 | 86479 | 70818984 |
Drug intolerance | 18.29 | 11.96 | 28 | 22953 | 225659 | 70679804 |
Drug hypersensitivity | 18.03 | 11.96 | 146 | 22835 | 262313 | 70643150 |
Gastrooesophageal reflux disease | 17.58 | 11.96 | 67 | 22914 | 90772 | 70814691 |
Vision blurred | 17.52 | 11.96 | 69 | 22912 | 94915 | 70810548 |
Infusion related reaction | 17.50 | 11.96 | 23 | 22958 | 197511 | 70707952 |
Aphonia | 17.27 | 11.96 | 18 | 22963 | 9233 | 70896230 |
Body temperature fluctuation | 17.27 | 11.96 | 12 | 22969 | 3547 | 70901916 |
Liver iron concentration abnormal | 17.20 | 11.96 | 4 | 22977 | 58 | 70905405 |
Mental status changes | 17.01 | 11.96 | 52 | 22929 | 63049 | 70842414 |
Exposure during pregnancy | 16.59 | 11.96 | 4 | 22977 | 87713 | 70817750 |
Coronary artery disease | 16.26 | 11.96 | 51 | 22930 | 62685 | 70842778 |
Speech disorder | 14.88 | 11.96 | 43 | 22938 | 50537 | 70854926 |
Iliac artery occlusion | 14.82 | 11.96 | 5 | 22976 | 294 | 70905169 |
Product complaint | 14.75 | 11.96 | 19 | 22962 | 12212 | 70893251 |
Urge incontinence | 14.42 | 11.96 | 7 | 22974 | 1058 | 70904405 |
Depression | 14.38 | 11.96 | 112 | 22869 | 198862 | 70706601 |
Blood pressure systolic increased | 14.34 | 11.96 | 46 | 22935 | 57213 | 70848250 |
Escherichia urinary tract infection | 14.30 | 11.96 | 19 | 22962 | 12588 | 70892875 |
Colitis ischaemic | 14.06 | 11.96 | 20 | 22961 | 14117 | 70891346 |
Neutropenia | 14.01 | 11.96 | 40 | 22941 | 257116 | 70648347 |
Neutrophil count decreased | 13.64 | 11.96 | 5 | 22976 | 83551 | 70821912 |
Stomatitis | 13.52 | 11.96 | 13 | 22968 | 128498 | 70776965 |
Bladder adenocarcinoma stage unspecified | 13.50 | 11.96 | 3 | 22978 | 35 | 70905428 |
Orthostatic hypotension | 13.35 | 11.96 | 42 | 22939 | 51701 | 70853762 |
Perforation | 13.28 | 11.96 | 7 | 22974 | 1258 | 70904205 |
Barrett's oesophagus | 13.22 | 11.96 | 6 | 22975 | 779 | 70904684 |
Psychotic disorder | 13.03 | 11.96 | 34 | 22947 | 37667 | 70867796 |
Cystitis | 12.95 | 11.96 | 39 | 22942 | 46902 | 70858561 |
Wound | 12.91 | 11.96 | 8 | 22973 | 98724 | 70806739 |
Dysphagia | 12.71 | 11.96 | 71 | 22910 | 112763 | 70792700 |
Mixed incontinence | 12.68 | 11.96 | 3 | 22978 | 47 | 70905416 |
Completed suicide | 12.61 | 11.96 | 35 | 22946 | 227100 | 70678363 |
Multiple organ dysfunction syndrome | 12.60 | 11.96 | 10 | 22971 | 108505 | 70796958 |
Body height decreased | 12.52 | 11.96 | 14 | 22967 | 7769 | 70897694 |
Dysarthria | 12.08 | 11.96 | 46 | 22935 | 62267 | 70843196 |
Hyperlipidaemia | 12.08 | 11.96 | 25 | 22956 | 23838 | 70881625 |
Increased appetite | 12.04 | 11.96 | 16 | 22965 | 10597 | 70894866 |
Malignant neoplasm progression | 12.03 | 11.96 | 13 | 22968 | 121726 | 70783737 |
Palpitations | 12.02 | 11.96 | 69 | 22912 | 110684 | 70794779 |
Urosepsis | 12.02 | 11.96 | 25 | 22956 | 23924 | 70881539 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD07 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D064804 | Urological Agents |
CHEBI has role | CHEBI:48876 | muscarinic antagonists |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:53784 | antispasmodics |
FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Increased Urinary Frequency | indication | ||
Torsades de pointes | contraindication | 31722008 | |
Dementia | contraindication | 52448006 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Prolonged QT interval | contraindication | 111975006 | |
Bladder outflow obstruction | contraindication | 236645006 | |
Pyloric obstruction | contraindication | 244815007 | |
Retention of urine | contraindication | 267064002 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Gastrointestinal hypomotility | contraindication | 421807004 | |
Poor metabolizer due to cytochrome p450 CYP2D6 variant | contraindication | 423629005 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Aggravated Glaucoma | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.83 | acidic |
pKa2 | 9.14 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 8.49 | CHEMBL | CHEMBL | |||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.57 | CHEMBL | CHEMBL | |||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.51 | CHEMBL | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 8.66 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 7.77 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.85 | CHEMBL | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.16 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.85 | CHEMBL | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.15 | CHEMBL | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 8.66 | CHEMBL | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.51 | CHEMBL |
ID | Source |
---|---|
4024113 | VUID |
N0000022118 | NUI |
D00646 | KEGG_DRUG |
124937-52-6 | SECONDARY_CAS_RN |
4021103 | VANDF |
4024113 | VANDF |
C0388753 | UMLSCUI |
CHEBI:9622 | CHEBI |
CHEMBL1382 | ChEMBL_ID |
DB01036 | DRUGBANK_ID |
CHEMBL1722209 | ChEMBL_ID |
D000068737 | MESH_DESCRIPTOR_UI |
443879 | PUBCHEM_CID |
360 | IUPHAR_LIGAND_ID |
6768 | INN_ID |
WHE7A56U7K | UNII |
119565 | RXNORM |
191519 | MMSL |
5600 | MMSL |
d04294 | MMSL |
007444 | NDDF |
007445 | NDDF |
109113000 | SNOMEDCT_US |
372570008 | SNOMEDCT_US |
386971005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Detrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-4541 | TABLET, FILM COATED | 1 mg | ORAL | NDA | 25 sections |
Detrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-4544 | TABLET, FILM COATED | 2 mg | ORAL | NDA | 25 sections |
Detrol LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5190 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | NDA | 29 sections |
Detrol LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5191 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | NDA | 29 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0010 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 25 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0010 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 25 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0018 | TABLET, FILM COATED | 2 mg | ORAL | ANDA | 25 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0018 | TABLET, FILM COATED | 2 mg | ORAL | ANDA | 25 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7163 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 26 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7163 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 26 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7164 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7164 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6592 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 20 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6593 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 20 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-706 | TABLET, EXTENDED RELEASE | 1 mg | ORAL | ANDA | 22 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-706 | TABLET, EXTENDED RELEASE | 1 mg | ORAL | ANDA | 22 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-707 | TABLET, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 22 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-707 | TABLET, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 22 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-189 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 21 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-189 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 21 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-189 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 21 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-190 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 21 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-190 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 21 sections |
TOLTERODINE TARTRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-190 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 21 sections |
Tolterodine Tartrate | Human Prescription Drug Label | 1 | 16571-126 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 21 sections |
Tolterodine Tartrate | Human Prescription Drug Label | 1 | 16571-127 | TABLET, FILM COATED | 2 mg | ORAL | ANDA | 21 sections |
DETROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-959 | TABLET, FILM COATED | 2 mg | ORAL | NDA | 23 sections |
Tolterodine tartrate | Human Prescription Drug Label | 1 | 27241-191 | CAPSULE, EXTENDED RELEASE | 2 mg | ORAL | ANDA | 26 sections |
Tolterodine tartrate | Human Prescription Drug Label | 1 | 27241-192 | CAPSULE, EXTENDED RELEASE | 4 mg | ORAL | ANDA | 26 sections |
Tolterodine Tartrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-239 | TABLET | 1 mg | ORAL | ANDA | 20 sections |